|
|
|
16.09.26 - 23:00
|
Onco-Innovations Announces Closing of Shares for Debt Settlement (The Newswire)
|
|
|
Calgary, Canada – September 16, 2026 – TheNewswire – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce the closing of its previously announced settlement of outstanding indebtedness (the "Debt Settlement") in the aggregate amount of $481,694 (collectively, the “Debt”) owed to certain insiders and consultants of the Company (collectively, the "Creditors"), by way of the issuance of an aggregate of 860,168 common shares of the Company (each, a "Share" and collectively, the "Shares"), at a deemed price of $0.56 per Share in full and final settlement of the Debt, pursuant to certain debt settlement agreements dated August 31, 2026 between the Company and each of the Creditors.
The issuance of Shares to RHM Management Inc., an entity controlled by David Antony, the Company's Chief Financial Officer and Corporate Secretary, and to Carnarvon Strategies-Health...
|
|
|
10.09.26 - 00:00
|
Onco-Innovations Provides Interim Report on Microsome Studies Across Three Species (The Newswire)
|
|
|
Calgary, Canada – September 9, 2026 – TheNewswire – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce, further to its news release dated June 26, 2026, that it has received interim results from the ongoing three-species liver microsome metabolism studies supporting the preclinical development of ONC010, the Company's lead nanoparticle-formulated PNKP inhibitor. The studies are evaluating the metabolism of A83B4C63, ONC010's active pharmaceutical ingredient (API), across human, rat and dog test systems. The original program was initiated to characterize intrinsic clearance, metabolic degradation pathways and species-specific metabolism.
The interim results indicate that A83B4C63 is metabolized in all three species evaluated, primarily through pathways characteristic of cytochrome P450 enzymes, with species differences in the rate of metabolism observed. System controls performed as expec...
|
|
|
09.09.26 - 00:00
|
Onco-Innovations Announces Shares for Debt Settlement (The Newswire)
|
|
|
Calgary, Canada – TheNewswire - September 8, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) announces that, on September 8, 2026, it entered into debt settlement agreements, each dated August 31, 2026 (collectively, the “Settlement Agreements”), with certain insiders and consultants of the Company (collectively, the “Creditors”) to settle an aggregate of $481,694 in outstanding indebtedness owed to the Creditors (collectively, the “Debt”). Pursuant to the Settlement Agreements, the Company will issue an aggregate of 860,168 common shares in the authorized share structure of the Company (each, a “Share” and collectively, the “Shares”) to the Creditors at a deemed price of $0.56 per Share in full settlement of the Debt (the “Debt Settlement”).
The issuance of Shares to RHM Management Inc., an entity controlled by David Antony, the Company's Chief Financial Officer and Corporate Secretary, a...
|
|
|
|
|
13.08.26 - 00:00
|
Onco-Innovations Advances ONC010 Polymer Development with Identification of Non-Tin Catalyst and Provides Integrated Update (The Newswire)
|
|
|
Calgary, Canada – August 12, 2026 – TheNewswire - Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce, further to its news release dated July 30, 2026, that Nanosoft Polymers ("Nanosoft") has identified a non-tin catalyst for use in the continued development of the polymer synthesis process supporting ONC010, the Company's lead nanoparticle-formulated inhibitor of Polynucleotide Kinase Phosphatase ("PNKP"). The identification builds on previously announced catalyst-evaluation activities aimed at improving the consistency and reproducibility of the polymer used in ONC010's nanoparticle formulation. The non-tin approach is expected to support the Company's strategy for controlling catalyst-related impurities and developing a well-characterized polymer manufacturing process suitable for future GMP manufacturing. Nanosoft will continue to evaluate the catalyst as part of the ongoing p...
|
|
|
31.07.26 - 00:00
|
Onco-Innovations Reports Progress Toward a Consistent and Scalable Polymer Manufacturing Process Supporting ONC010 (The Newswire)
|
|
|
Vancouver, Canada – July 30, 2026 - TheNewswire – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce, further to its news release dated June 30, 2026, progress with respect to its collaborative polymer development program with Nanosoft Polymers ("Nanosoft"), including process optimization and catalyst evaluation activities aimed at improving the consistency and uniformity of the polymer used in ONC010's nanoparticle formulation. The work forms part of the chemistry, manufacturing and controls ("CMC") development of ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase ("PNKP") inhibitor.
A central focus of the current work is the evaluation of catalyst systems and refinement of polymer synthesis conditions and reaction parameters aimed at improving control of the polymer's polydispersity index ("PDI"), a key measure of molecu...
|
|
|
29.07.26 - 23:00
|
Onco-Innovations Announces Initial Closing of Notional CAD$5 Million Performance-Based Funding Arrangement (The Newswire)
|
|
|
Vancouver, Canada – July 29, 2026 – TheNewswire - Onco-Innovations Limited (CBOE: ONCO) (“Onco” or the “Company”) is pleased to announce that it has closed its previously announced non-brokered private placement financing with Sorbie Bornholm LP (“SBLP”) and Sorbie Investments LLP (“SILP” and, together with SBLP, “Sorbie”) representing a notional subscription amount of approximately CAD$5,000,000 (the “Offering”), before giving effect to the Sharing Arrangement (as defined below), which may result in the Company ultimately receiving an amount that is greater or less than such notional subscription amount.
The Offering was completed as a non-brokered private placement in reliance on available prospectus exemptions under applicable securities laws. The securities issued under the Offering will not be subject to a Canadian statutory hold period or Canadian resale legend.
Pursuant to the Offering, the Company issued an aggregate of 7,936,508 units of the Company (each, a ?...
|
|
|
27.07.26 - 23:00
|
Onco-Innovations Announces Repricing of Previously Announced Performance-Based Funding Arrangement (The Newswire)
|
|
|
Vancouver, Canada – July 27, 2026 – TheNewswire - Onco-Innovations Limited (CBOE: ONCO) (“Onco” or the “Company”) announces that, further to its previously announced non-brokered private placement financing representing a notional subscription amount of approximately CAD$5,000,000 (the “Offering”), the Company and the arm's length institutional investors, being Sorbie Bornholm LP (“SBLP”) and Sorbie Investments LLP (“SILP” and, together with SBLP, “Sorbie”), have agreed to reprice the Offering to provide for the issuance of units of the Company (each, a “Unit”) at a revised notional price of CAD$0.63 per Unit.
Based on the revised notional price of CAD$0.63 per Unit, the Company expects to issue an aggregate of 7,936,508 Units pursuant to the Offering, with each Unit comprised of one common share of the Company (each, a “Share”) and one common share purchase warrant of the Company (a “Warrant”). Each Warrant will be exercisable at CAD$0.77 per Share for a per...
|
|
|
17.07.26 - 00:01
|
Onco-Innovations Initiates ADME Studies Supporting Development of ONC010 (The Newswire)
|
|
|
Vancouver, Canada – July 16, 2026 – TheNewswire - Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) announces, further to its news release dated May 8, 2026, the initiation of key absorption, distribution, metabolism and excretion ("ADME") studies for ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. The studies are designed to characterize ONC010's pharmacokinetic and metabolic profile and support the continued IND-enabling development of the program.
The initial ADME work is focused on metabolism of the active pharmaceutical ingredient (API) in the ONC010 lead drug candidate. These data are intended to support the Company's broader development strategy by informing manufacturing activities, formulation optimization, toxicology studies and future clinical translation. The studies are expected to contribute to the growing body of preclinical...
|
|
|
16.07.26 - 00:01
|
Onco-Innovations Announces Entry into Loan Agreements (The Newswire)
|
|
|
Vancouver, Canada – July 15, 2026 - TheNewswire – Onco-Innovations Limited (CBOE: ONCO) (“Onco” or the “Company”) announces that it has entered into three loan agreements with certain lenders providing for loans to the Company in the aggregate principal amount of up to CAD$280,000 (collectively, the “Loans”).
Two of the Loans are from arm's length shareholders of the Company (together, the “Shareholder Loans”), pursuant to which the Company may make demand for the principal amounts of up to CAD$20,000 and CAD$60,000, respectively. The Shareholder Loans bear interest at a rate of 15% per annum, calculated monthly, and are repayable on demand. The Shareholder Loans may be prepaid in whole or in part at any time without premium or penalty, with any prepayment to be credited first to accrued but unpaid interest and then to principal.
The third Loan is from Dr. Islam Mohamed, the Chief Medical Officer of the Company, in the amount of CAD$200,000 (the “Other Loan”). The Other L...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
